A Tailored Dose of Tenofovir Could Reduce Its Impact on Bone Mass in HIV Type 1-Infected Children and Adolescents: A Report from 5 Years of Clinical Experience
Restricted accessLetterFirst published online December, 2010
A Tailored Dose of Tenofovir Could Reduce Its Impact on Bone Mass in HIV Type 1-Infected Children and Adolescents: A Report from 5 Years of Clinical Experience
PENTA Steering Committee. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med, 2009; 10:591–613.
2.
PurdyJB, GafniRI, ReynoldsJC, ZeichnerS, HazraR. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr, 2008; 152:582–584.
3.
RossoR, VignoloM, ParodiAet al.Bone quality in perinatally HIV-infected children: Role of age, sex, growth, HIV-infection and antiretroviral therapy. AIDS Res Hum Retroviruses, 2005; 21:927–932.
4.
BaroncelliGI, FedericoG, VignoloMet al.The Phalangeal Quantitative Ultrasound Group. Cross-sectional reference data for phalangeal quantitative ultrasound from early childhood to young-adulthood according to gender, age, skeletal growth, and pubertal development. Bone, 2006; 39:159–173.
5.
BarkmannR, RohrschneiderW, VierlingMet al.German pediatric reference data for quantitative transverse transmission ultrasound of finger phalanges. Osteoporos Int, 2002; 13:55–61.
6.
GafniRI, HazraR, ReynoldsJCet al.Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: Impact on bone mineral density in HIV-infected children. Pediatrics, 2006; 118:e711–e718.
7.
GiacometV, MoraS, MartelliL, MerloM, SciannambloM, ViganòA. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr, 2005; 40:448–450.
